Bionaturis (ticker BNT-MAB), an international reference company providing biological drugs, has just signed a new collaborative agreement with a multinational company to develop a new product that meets an increasing need of the livestock industry. It is a new first-in-class drug to induce ovulation in livestock prior to artificial insemination.

According to the agreement, Bionaturis will make use of its proprietary system FLYLIFE to develop the product and will also perform efficacy and safety tests in animal models, while the multinational will validate these results in its facilities, performing field trials with the intended specie.

The agreement includes exclusive licensing option rights for the multinational company, which forecasts a minimum potential market of 20-25 USD million for this product.

Victor Infante, Bionaturis’ CEO, commented: “The goal of this collaborative development program is to enable the multinational company to replace the current standard treatment with a safe, cost-effective, scalable recombinant first-in-class solution produced by our technology.”

The new agreement represents another important milestone for Bionaturis in its goal of reaching co-development agreements with large international laboratories and standardize its FLYLIFE platform as reliable alternative system of making cutting-edge medicines.

 

FLYLIFE platform

FLYLIFE is a revolutionary Plug&Play platform designed to produce cost-effective biological drugs at an industrial scale.

Bionaturis offers product licenses, based on its proprietary FLYLIFE platform, providing partners full support for protein therapeutics and vaccines development.